JP Morgan Chase
ABMD

JP Morgan Chase’s Abiomed Inc ABMD Stock Holding History

JP Morgan Chase’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,200
Closed -$2.42M – 5861
2019
Q4 		$2.42M Buy
+14,200
New +$2.63M ﹤0.01% 3244
2019
Q3 		– Sell
-20,000
Closed -$5.1M – 6047
2019
Q2 		$5.1M Buy
+20,000
New +$5.31M ﹤0.01% 2633
2019
Q1 		– Sell
-22,900
Closed -$7.44M – 6130
2018
Q4 		$7.44M Buy
+22,900
New +$7.95M ﹤0.01% 2252

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's ABMD Position: Q4 2022 in Review

JP Morgan Chase sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 218,051 shares — an estimated $53.6M sold.

JP Morgan Chase first reported a position in ABMD in Q2 2013 and held it in 32 quarters. The position peaked at $187M in Q2 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • JP Morgan Chase reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Chase sold 218,051 Abiomed Inc shares in Q4 2022, an estimated $53.6M.
  • JP Morgan Chase first reported a position in Abiomed Inc in Q2 2013 and held it in 32 quarters.
  • JP Morgan Chase's Abiomed Inc position peaked at $187M in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.